Dupilumab treatment reduces serum SCCA2 levels in patients with atopic dermatitis
Dupilumab treatment reduces serum SCCA2 levels in patients with atopic dermatitis
About this item
Full title
Author / Creator
Publisher
Tokyo: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
Tokyo: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Dupilumab treatment reduced serum SCCA2 levels in patients with atopic dermatitis. Interestingly, even though the skin eruptions had not yet fully disappeared, serum SCCA2 levels were reduced well to below normal by the administration of dupilumab.
Alternative Titles
Full title
Dupilumab treatment reduces serum SCCA2 levels in patients with atopic dermatitis
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_8eb6d488e4a9497f96df4165fcc22abb
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_8eb6d488e4a9497f96df4165fcc22abb
Other Identifiers
ISSN
2574-4593
E-ISSN
2574-4593
DOI
10.1002/cia2.12282
